Srebps: a potential therapeutic target for metabolic diseases
- Author:
De-Zhen GENG
1
Author Information
- Publication Type:Journal Article
- Keywords: CAMP; Fat metabolism; Insulin; Liver X receptor; Metabolic diseases; Sterol regulatory element binding proteins
- From: Chinese Pharmaceutical Journal 2019;54(15):1205-1210
- CountryChina
- Language:Chinese
- Abstract: Sterol regulatory element binding proteins (SREBPs) are the major transcription factors regulating cholesterol, fatty acid and triglyceride biosynthesis and control the expression of key genes such as lipogenesis and uptake. In this review, we summarize the processing of SREBPs and their interactions with insulin, cyclic adenosine monophosphate (cAMP), and liver X receptor (LXR) for the synthesis and metabolism of lipid, and combine the latest researches to illustrate the function of SREBPs. These findings suggest that inhibition of SREBPs can be a new strategy for the treatment of metabolic diseases, such as type Ⅱ diabetes, insulin resistance, fatty liver, atherosclerosis and tumors.
